Subtype
Malignant Neck Neoplasm
CI-CAN-00001148Explore in graph →
607 active trials11 approved drugs67 evidence items
- NCIt
- C4940
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001148Explore in graph →
Clinical trials
2,146 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07524413 | Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 514 | Sun Yat-sen UniversityOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT05696548 | Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) | active not recruiting | Phase 2 | 51 | National Cancer Center Hospital EastOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06141369 | Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) | recruiting | N/A | 21 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03975231 | Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer | recruiting | Phase 1 | 6 | City of Hope Medical CenterOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05483374 | The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers(EURACAN) | recruiting | — | 13,600 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 3 | Apr 3, 2026 | clinicaltrials |
| NCT05587543 | Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma | recruiting | Early Phase 1 | 24 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT01898494 | Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer | active not recruiting | Phase 2 | 519 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05387915 | Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer | active not recruiting | Phase 2 | 33 | Emory UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06915727 | An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors | recruiting | Phase 3 | 20 | Mayo ClinicOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06158360 | An Observational Study on Postoperative Symptoms After Thyroidectomy (POS-T) | recruiting | — | 500 | Ilsan Cha hospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07247201 | Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients(AlloNK1) | not yet recruiting | Phase 1 / Phase 2 | 31 | Singapore General HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06077643 | Workshops and Exchange Groups for Laryngectomized Patients(GELAT) | recruiting | — | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06207188 | Identification and Differentiation of Thyroid Nodules by Acoustic Imaging and Viscoelastic Parameters | recruiting | — | 650 | Mayo ClinicOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03410615 | Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC | active not recruiting | Phase 2 | 129 | Canadian Cancer Trials GroupNETWORK | 4 | Mar 24, 2026 | clinicaltrials |
| NCT06323460 | Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer | recruiting | Phase 2 | 45 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)(MABEL) | active not recruiting | Phase 1 | 38 | Baylor College of MedicineOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06146764 | CEUS Improves the Diagnostic Performance of SRSS of Thyroid Carcinoma | recruiting | — | 800 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06220656 | TRAIL Study: Feasibility and Pilot | recruiting | N/A | 20 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06554158 | De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers | recruiting | N/A | 30 | Georgetown UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06316895 | The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma | recruiting | — | 3,772 | Chinese PLA General HospitalOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07320963 | Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. | not yet recruiting | Phase 1 / Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 0 | Mar 20, 2026 | clinicaltrials |
| NCT04211337 | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer(LIBRETTO-531) | active not recruiting | Phase 3 | 291 | Loxo Oncology, Inc.INDUSTRY | 20 | Mar 19, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05539638 | The Role of Circulating Tumour DNA in Head and Neck Cancer | recruiting | — | 250 | University of EdinburghOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07092514 | Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC) | recruiting | Phase 2 | 34 | Washington University School of MedicineOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07362979 | Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 2 | 243 | Sun Yat-sen UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07459296 | Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC | recruiting | Phase 3 | 266 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07473518 | Thyroid Carcinoma in Cancer Patients Undergoing Radiotherapy | recruiting | — | 2,550 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03360890 | Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors(iPRIME) | active not recruiting | Phase 2 | 46 | University of ChicagoOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06030440 | De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck(DIREKHT2) | recruiting | Phase 2 / Phase 3 | 508 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04742608 | Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer | recruiting | — | 250 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04030455 | Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer | active not recruiting | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07412314 | Proton Therapy for Recurrent Nasopharyngeal Carcinoma | recruiting | N/A | 52 | Guangzhou Concord Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07457099 | Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | — | 85 | Zhujiang HospitalOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03570021 | ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer(ESTIMABL3) | active not recruiting | Phase 3 | 352 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 3 | Mar 6, 2026 | clinicaltrials |
| NCT06239727 | Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response | recruiting | Phase 3 | 593 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT02597426 | Nasopharyngeal Carcinoma Post IMRT | active not recruiting | — | 108 | University Health Network, TorontoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06868433 | TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer | recruiting | Phase 1 | 40 | Emory UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07327216 | Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 180 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06524167 | RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer | recruiting | — | 80 | Fudan UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06554652 | Selective Neck Dissection Versus Modified Neck Dissection in PTC | recruiting | Phase 3 | 250 | Fudan UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06558981 | Adjuvant Radiotherapy in High Risk Locally Advanced DTC | recruiting | Phase 3 | 124 | Fudan UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07044635 | Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.(RAD RAPTORS) | recruiting | Phase 2 | 42 | University of UtahOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07193186 | Anlotinib and Benmelstobart in DTC | not yet recruiting | Phase 2 | 23 | Fudan UniversityOTHER | 0 | Feb 27, 2026 | clinicaltrials |
| NCT07436455 | F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer(NISDETECT) | recruiting | N/A | 50 | Ankara UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07438847 | 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer | recruiting | Phase 1 | 12 | SHAOYAN LIUOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05261750 | Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer | active not recruiting | Phase 1 / Phase 2 | 15 | PT. Prodia Stem Cell IndonesiaINDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 54 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT05837221 | Microbiome in Head and Neck Squamous Cell Carcinoma | recruiting | — | 60 | University of Colorado, DenverOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT03174275 | Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 2 | 39 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 13, 2026source: clinicaltrials